Company News
Technology access partnership to advance NDD research
May 09 2024
Drug discovery startup Neurolentech, focused on epilepsy and related genetic neurodevelopmental disorders (NDDs), has formed an agreement enabling Kaerus Bioscience to access its NDD Drug Discovery platform and leverage its proprietary cell models and assays for functional screens, to drive advances in this field of research.
A spin out from IST Austria, Neurolentech's Platform comprises a vast collection of human-derived neuronal cell lines from patients with monogenic and complex neurodevelopmental disorders. Kaerus Bioscience will be using the platform to model the complex neural networks underlying clinical features of genetic NDDs at a cellular level, as well as to investigate the therapeutic potential of its small molecule pipeline for numerous genetic syndromes preclinically.
Fiona Nielsen, CEO of Neurolentech, said, “We are excited to collaborate with Kaerus Bioscience in advancing their programs in the field of neurodevelopmental disorders. Our platform's unique capabilities offer unparalleled insights into disease mechanisms, facilitating the development of novel therapies."
Robert Ring, CEO of Kaerus Bioscience, added, "Our partnership with Neurolentech underscores Kaerus’ commitment to leveraging cutting-edge technology and innovative platform approaches to accelerating the discovery of treatments for patients with genetic disorders of neurodevelopment.”
More information online
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
May 21 2024 Lagos, Nigeria
May 22 2024 Basel, Switzerland
Scientific Laboratory Show & Conference 2024
May 22 2024 Nottingham, UK
May 23 2024 Beijing, China
May 28 2024 Tel Aviv, Israel